4Degrees is a software company. They specialize in providing AI-enabled relationship management and intelligence software. They are a relationship intelligence CRM platform built for relationship-centric industries, including Banking and Commercial Real Estate.

Acesion Pharma is a Danish biotech company founded in 2011. We are aiming to develop more efficacious and safer drugs for the treatment of Atrial Fibrillation (AF), the most common type of cardiac arrhythmia. The scientific foundation of Acesion Pharma is the novel concept of treating AF by inhibiting the so-called SK channels. These are ion channels present in the heart where they are relevant for regulating the cardiac rhythm. Blocking this ion channel with a selective drug molecule constitutes a novel and promising target for developing improved treatment of AF.

Actio Biosciences is a clinical-stage biotechnology company developing genetics-led precision therapies for rare and common diseases, with lead small molecule programs targeting KCNT1-related epilepsy (ABS-1230) and Charcot-Marie-Tooth disease type 2C (ABS-0871). The company is advancing these programs through preclinical and Phase 1 studies toward patient trials.

Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, Cystic Fibrosis, and Asthma.

Aeva’s mission is to bring the next wave of perception to a broad range of applications from automated driving, manufacturing automation and smart infrastructure, to robotics and consumer devices. Aeva is accelerating autonomy with its groundbreaking perception platform that integrates lidar-on-chip technology, system-on-chip processing, and perception algorithms onto silicon leveraging silicon photonics. Aeva 4D LiDAR sensors uniquely detect velocity and position simultaneously, allowing automated devices like vehicles and robots to make more intelligent and safe decisions.

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.

Aim Security specializes in providing comprehensive security solutions for enterprises adopting generative Artificial Intelligence (AI). The company's platform is designed to address the unique security challenges posed by AI, including data exposure, supply chain vulnerabilities, and malicious outputs.

AirEye is the only solution that provides full protection against any form of airborne attacks launched against the organizational network. Digital airborne attacks leverage wireless communications (incl. WiFi, cellular, 5G, and Bluetooth) in the corporate airspace in order to gain unauthorized network access, hijack the network, or leak data. These are also common entry points in an APT attack. The platform monitors all wireless communications in real-time. Any violation of corporate security is detected and attacks are automatically blocked. Findings are sent to the company SIEM, eliminating the need for platform management and alert chasing. AirEye Dome is a SaaS platform that seamlessly complements your existing network security infrastructure, without the need for architectural changes or messy integrations. The platform is deployed at various industries, including finance, banking, telco, healthcare, manufacturing, retail, and aerospace.

Alkymi is the first end-to-end solution for turning your private markets data into actionable insights. With AI-powered document workflows, Alkymi is transforming how the private markets industry accesses their data—empowering leading firms like SimCorp, Northwestern Mutual, and Strategic Investment Group to scale their investments, service more clients, and respond faster to changing markets.

Almanac is the most powerful platform for async collaboration. A modern doc editor with version control to manage changes across docs and automated workflows for reviews, revisions, and suggestions. Built to give innovative companies, distributed teams, and the world's most ambitious people power, organization, and transparency—so they can collaborate with focus and speed. Join us in a world with less meetings and messages!

AltScore enables any B2B company to create and manage their own credit products. Our 'Rails of Lending' APIs shorten the launch time of new lending products from years to just weeks, while delivering fintech-level capabilities at every stage of the loan process—from onboarding and underwriting to collections and renovations.

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. They aim to prevent cancer by treating precancerous lesions caused by HPV. Their programs are in clinical trials for high-grade anal intraepithelial neoplasias (AIN 2,3) and high-grade cervical intraepithelial neoplasias (CIN 2,3).